Temsirolimus (CCI-779, NSC 683864) - ≥98%, high purity , FK506-binding protein 1A inhibitor, CAS No.162635-04-3, FK506-binding protein 1A inhibitor

Item Number

T126606

• Synonyms: AB01274736-01 | DTXSID2040945 | CBPNZQVSJQDFBE-FUXHJELOSA-N | NCGC00167518-09 | TEMSIROLIMUS (MART.) | temsirolimusum | BRD-K08177763-001-02-6 | L01XE09 | TEMSIROLIMUS [INN] | TEMSIROLIMUS [VANDF] | MFCD00934421 | Temsirolimus (CCI-779, NSC 683864) | Tox2
• Specifications & Purity: Moligand™, ≥98%
• Biochemical and Physiological Mechanisms: Temsirolimus (also known as CCI-779) is a recently developed mTOR inhibitor. with improved aqueous solubility and more favorable pharmaceutical properties compared with the parent compound rapamycin.Selective mTORC1 complex inhibitor (IC 50 = 1.76 µM). Wa
• Storage Temp: Store at -20°C
• Shipped In: Ice chest + Ice pads
• Grade: Moligand™
• Action Type: INHIBITOR
• Mechanism of action: FK506-binding protein 1A inhibitor
• Note: Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

Product Description

Temsirolimus (CCI-779) directly inhibits mTOR kinase activity with IC50 values of 1.76 ± 0.15 μM.
A potent inhibitor of FRAP (mTOR) kinase activity

application：

Temsirolimus is used as a rapamycin derivative with anti-cancer activity that inhibits mTOR. Temsirolimus is an antiproliferative and antiangiogenic, the first-in-class mTOR inhibitor approved for the treatment of patients with advanced poor prognosis renal cell carcinoma.